Mechanism of Action
Kisspeptin-10 acts at the apex of the reproductive axis, gating GnRH neuron firing.
KISS1R Activation on GnRH Neurons
Kisspeptin-10 binds KISS1R (GPR54) on hypothalamic GnRH neurons, activating Gq/11-coupled PLC-IP3 signaling that rapidly depolarizes the neuron and triggers GnRH pulse secretion into the hypophyseal portal circulation. This is the most direct stimulus for LH/FSH release available pharmacologically.[1]LH Surge and Testosterone/Estrogen Stimulation
GnRH pulses from kisspeptin activation drive LH and FSH surges from the anterior pituitary. In men: LH stimulates Leydig cells to produce testosterone. In women: LH/FSH stimulate follicular development, estradiol production, and ovulation. Kisspeptin-10 thus provides a natural, axis-respecting alternative to exogenous LH/hCG injections.[2]Sexual Arousal via Limbic Circuits
KISS1R is also expressed in limbic regions (amygdala, hippocampus) independent of GnRH neurons. Kisspeptin-10 administration increases sexual arousal and olfactory-sexual responsiveness through these extrahypothalamic circuits, a mechanism distinct from its reproductive endocrine effects.[3]Research Overview
Ovulation Induction and Fertility
Phase II ClinicalPhase II trials demonstrate kisspeptin-10 can reliably trigger ovulation in IVF protocols as a GnRH agonist trigger alternative with significantly lower risk of ovarian hyperstimulation syndrome (OHSS). A 2014 Lancet paper showed successful IVF births using kisspeptin-10 as the ovulation trigger in high-OHSS-risk patients.[1]
Male Hypogonadism and Testosterone
Phase II ClinicalPhase II in hypogonadotropic hypogonadism men shows pulsatile kisspeptin-10 restores LH pulsatility and testosterone. Unlike exogenous testosterone, kisspeptin stimulates endogenous production while preserving testicular size and fertility, a key advantage for men who want hormonal support without suppressing the HPG axis.[2]
Sexual Function
Moderate EvidenceHuman studies show kisspeptin-10 IV infusion increases sexual arousal and mesolimbic activity on fMRI, and improves sexual psychophysiology measures in hypogonadal men and women. The limbic KISS1R pathway provides a unique CNS sexual arousal mechanism distinct from testosterone levels.[3]
Post-Cycle Recovery (HPG Axis)
EmergingResearch use application: kisspeptin-10 may accelerate HPG axis recovery after exogenous androgen or GH cycle suppression by directly stimulating GnRH neurons. This could offer an upstream activation point complementary to SERMs (clomiphene) and hCG currently used in PCT.[2]
Calculate your Kisspeptin-10 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| HPG axis / testosterone support | 0.5–1 mg | Every 90 min (pulsatile) or 2–3× daily | Subcutaneous |
| Fertility / ovulation trigger (female) | 6.4–9.6 nmol/kg (clinical IV) approx. 1–2 mg SC | Single dose (timed) | Subcutaneous |
| Sexual function / libido | 1 mg | As needed, 45 min before | Subcutaneous |
For HPG axis support: pulsatile dosing every 90 min mirrors physiological GnRH pulse frequency. Short half-life requires frequent dosing for sustained effect. For libido applications: single pre-activity dosing 45-60 min before. Effects on testosterone require consistent pulsatile dosing over days to accumulate.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
Kisspeptin-10 has Phase II clinical safety data from reproductive medicine trials.
Well tolerated: No dose-limiting toxicities in Phase II fertility and hypogonadism trials. Mild injection site reactions are the most common adverse event.
Desensitization: Continuous (non-pulsatile) kisspeptin administration causes KISS1R downregulation and paradoxical suppression of GnRH, similar to GnRH agonist paradox. Pulsatile dosing is essential for sustained stimulatory effect.
OHSS risk: Lower than standard GnRH agonist trigger for IVF, which is one of its clinical advantages.
Not FDA approved: Research compound. Phase II evaluation ongoing in reproductive endocrinology.
References
- [1]Jayasena CN, et al. "Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization." J Clin Invest. 2014;124(8):3667-3677.
- [2]Dhillo WS, et al. "Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males." J Clin Endocrinol Metab. 2005;90(12):6609-6615.
- [3]Comninos AN, et al. "Kisspeptin modulates sexual and emotional brain processing in humans." J Clin Invest. 2017;127(2):709-719.